KyungDong Pharm home
Prescription Medicines

Cansata Plus Tab.

Product Category
ARB-based high blood pressure treatment
Active Ingredients
Candesartan cilexetil, hydrochlorothiazide
Appearance
A light orange, oblong tablet with a score line on one side.
Reimbursement Code
648102980
View Regulatory Information on the MFDS Portal ↗
1. Composition and Strength : 1 tablet
- Active ingredient: Candesartan cilexetil (JP) ---------- 16mg
Hydrochlorothiazide (EP) — 12.5 mg
- Additives (animal-derived ingredients): Lactose hydrate (cow, milk)
- Other additives: magnesium stearate, corn starch, red iron oxide, calcium carboxymethyl cellulose, polyethylene glycol 400, hydroxypropyl cellulose, yellow iron oxide.

2. Efficacy/Effectiveness
Essential hypertension for which individual component treatments are not effective enough

3. Usage/Dosage
The recommended dosage of this medicine is 1 tablet once a day, taken regardless of meals.
1) Adults: Before switching to this drug, the dose of candesartan cilexetil should be adjusted first. When clinically appropriate, direct conversion from monotherapy to this drug may be considered. Antihypertensive effects are mostly achieved within 4 weeks of starting administration.

2) Elderly: There is no need to adjust the dosage of this drug for elderly people.

3) Patients with intravascular volume depletion: It is recommended to adjust the dose of candesartan cilexetil in patients at risk of hypotension, such as patients with the possibility of effective blood volume depletion (the initial dose of candesartan cilexetil in these patients is 4 mg).

4) Patients with renal impairment: In patients with mild to moderate renal impairment with a creatinine clearance of 30-80ml/min/1.73㎡ BSA, first consider adjusting the dose of candesartan cilexetil before switching to this drug (the initial dose of candesartan cilexetil in these patients is 4 mg). Do not administer to patients with severe renal impairment (creatinine clearance less than 30ml/mim/1.73㎡ BSA)

5) Patients with hepatic impairment: It is recommended to first adjust the dose of candesartan cilexetil before administering this drug to patients with mild to moderate hepatic impairment (the initial dose of candesartan cilexetil in these patients is 2 mg). Do not administer to patients with severe hepatic impairment or cholestasis.

4. Precautions for use
1. Warning
1) Fetal/neonatal morbidity and mortality
When drugs that act directly on the renin-angiotensin-aldosterone system, such as this drug, are administered to a pregnant woman (second or third trimester of pregnancy), fetal and neonatal damage and death may occur. Therefore, if pregnancy is confirmed while taking this drug, administration of this drug should be discontinued immediately. (Refer to the ‘Administration for pregnant and lactating women’ section)

2. Do not administer to the following patients
1) Patients who have hypersensitivity to any component of this drug or sulfonamide derivative drugs
(Hydrochlorothiazide is a sulfonamide derivative)
2) Pregnant women, women considering pregnancy, and lactating women
3) Patients with acute or severe renal impairment (creatinine clearance less than 30ml/min/1.73m2 BSA)
4) Patients with severe hepatic impairment or cholestasis
5) Patients with hereditary angioedema or a history of angioedema during treatment with ACE inhibitors or angiotensin II receptor antagonists
6) Gout patients
7) Patients with primary hyperaldosteronism (do not respond well to this drug)
8) Patients with anuria
9) Patients with low sodium/hypokalemia and hypercalcemia
10) Patients with Addison's disease
11) Combination use with aliskiren-containing preparations in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2)
12) Since this drug contains lactose, it should not be administered to patients with genetic problems such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption.

3. Administer with caution to the following patients:
1) In patients with intravascular volume depletion or sodium deficiency, symptomatic hypotension may occur, as with other drugs that affect the renin-angiotensin-aldosterone system, so it is recommended not to administer this drug until symptoms improve.
2) Because small changes in body fluid and electrolyte balance can cause hepatic coma, thiazides must be administered with caution to patients with hepatic impairment or advanced liver disease. There is no experience administering this drug to patients with liver failure.
3) Aortic and mitral valve stenosis (hypertrophic obstructive cardiomyopathy): As with other vasodilators, special caution is required in patients with hemodynamically related aortic or mitral valve stenosis or hypertrophic obstructive cardiomyopathy.
4) Patients with hyperkalemia (can worsen symptoms)
5) Patients with severe coronary arteriosclerosis or cerebral arteriosclerosis (if rapid diuresis occurs, blood concentration may occur due to rapid decrease in plasma volume, which may lead to thromboembolism.)
6) Patients after sympathectomy (the blood pressure lowering effect of this drug may increase)
7) Patients with renal artery stenosis (there is a risk of rapid deterioration of renal function due to a decrease in renal blood flow or a decrease in glomerular filtration pressure).
8) Patients with renal impairment (see directions and dosage) or patients who have undergone a kidney transplant
9) Patients with hepatic impairment (refer to directions and dosage)
10) Patients receiving digitalis, glucocorticosteroids, or adrenocorticotropic hormones
11) Patients with hyperparathyroidism
12) Patients undergoing salt restriction therapy
13) Patients with diarrhea and vomiting
14) Elderly people
15) Patients who have gout or diabetes in themselves or their parents or siblings
16) Dual blockade of the renin-angiotensin-aldosterone system (RAAS): Concurrent use with other drugs that affect the renin-angiotensin-aldosterone system (RAAS), such as angiotensin II receptor antagonists (ARB), ACE inhibitors, or aliskiren, is not recommended. In patients with diabetic kidney disease, ACE inhibitors and angiotensin receptor antagonists should not be used together.
17) Non-melanoma skin cancer (NMSC)
Two epidemiological studies based on the Danish National Cancer Registry reported an increased risk of non-melanoma skin cancer, including basal cell and squamous cell carcinoma, with increasing cumulative exposure to hydrochlorothiazide. The photosensitizing effects of hydrochlorothiazide may contribute to the development of non-melanoma skin cancer.
Inform patients taking hydrochlorothiazide about the risk of non-melanoma skin cancer. Advise them to check their skin regularly for new lesions and report any suspicious skin lesions. Recommend preventive measures to minimize the risk, including limiting exposure to sunlight and ultraviolet radiation and using appropriate protection when exposed. Suspicious skin lesions should be examined promptly, including by biopsy where appropriate. Reconsider the use of hydrochlorothiazide in patients with a history of non-melanoma skin cancer.

4. Adverse reactions
1) Adverse reactions to candesartan and hydrochlorothiazide combination medication
In placebo-controlled clinical trials with candesartan cilexetil/hydrochlorothiazide, adverse reactions were mild, transient, and similar to placebo. The incidence of adverse reactions was independent of age or gender. The proportion of patients discontinuing treatment due to adverse events was similar between ZELJANZ (2.3-3.3%) and placebo (2.7-4.3%).
In a double-blind placebo-controlled study administering up to 16/12.5 mg of candesartan and hydrochlorothiazide, clinical adverse reactions with an incidence of more than 1% over 8 weeks regardless of causal relationship were as follows.
※ Please check the attached document for details.

Atrioventricular block and vomiting did not occur in the placebo group, but occurred at an incidence of 0.5% to <1% in the candesartan cilexetil/hydrochlorothiazide group.

In a double-blind study administering candesartan cilexetil/hydrochlorothiazide 32/12.5mg and 32/25mg, clinical adverse reactions with an incidence of more than 1% over 8 weeks regardless of causal relationship were as follows.
※ Please check the attached document for details.

In general, this drug does not have a significant effect on routine clinical tests. Elevations of blood sugar, plasma uric acid, and ALAT (SGPT) occurred somewhat more frequently in the Xeroxin-treated group (1.0%, 1.1%, and 0.9%, respectively) compared to the placebo group (0.2%, 0.4%, and 0%, respectively). In one patient treated with this drug, a slight decrease in hemoglobin and an increase in serum ASAT (SGOT) were observed. Increases in creatinine, urea, and potassium and decreases in sodium were observed.

In general, candesartan cilexetil/hydrochlorothiazide does not significantly affect routine clinical parameters. Elevations of blood sugar, serum uric acid, and ALT (SGPT) occurred somewhat more frequently in the candesartan cilexetil/hydrochlorothiazide group (1.0%, 1.1%, and 0.9%, respectively) compared to the placebo group (0.2%, 0.4%, and 0%, respectively). In one patient receiving candesartan cilexetil/hydrochlorothiazide, a slight decrease in hemoglobin and an increase in serum AST (SGOT) were observed. Increases in creatinine, urea, and potassium and decreases in sodium were observed.

2) Adverse reactions to single ingredients
The following terms were used to classify the frequency of adverse reactions:
Very common (≥ 1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), frequency unknown.

Adverse reactions reported for candesartan cilexetil in post-marketing experience include:
※ Please check the attached document for details.

The following adverse reactions have been reported with hydrochlorothiazide monotherapy, predominantly at doses of 25 mg or more:
※ Please check the attached document for details.

3) Domestic post-marketing survey results
As a result of a safety evaluation conducted on 2,304 cases during the post-marketing surveillance period in Korea, the incidence of adverse reactions was reported to be 10 to 11 cases (0.43%), regardless of causal relationship. Among these, the incidence of adverse reactions for which a causal relationship with drugs cannot be ruled out is as follows: 9 out of 8 cases (0.35%).

A. Central and peripheral nervous system abnormalities: dizziness 0.13% (3 cases/2,304 cases), headache 0.04% (1 case/2,304 cases)
B. Systemic abnormalities: edema 0.04% (1 case/2,304 cases)
c. Musculoskeletal abnormalities: muscle pain 0.04% (1 case/2,304 cases)
D. Metabolic and nutritional abnormalities: hypercalcemia 0.04% (1 case/2,304 cases)
E. Gastrointestinal abnormalities: Nausea 0.04% (1 case/2,304 cases)
Bar. Hearing and vestibular abnormalities: Otalgia 0.04% (1 case/2,304 cases)

Among these, there was one case each of muscle pain and ear pain (0.04%) as unexpected new adverse drug reactions that were not listed in the current approval, and no serious adverse reactions were reported.

5. General precautions
1) Other drugs that affect the renin-angiotensin-aldosterone system, such as ACE inhibitors, may increase blood urea and creatinine levels when renal artery stenosis occurs in patients with bilateral renal artery stenosis or in patients with only one kidney. Similar effects may occur with angiotensin II receptor antagonists, although there have been no reports regarding administration of this drug.
2) Renal impairment/kidney transplantation: When administering this drug to patients with renal impairment, it is recommended to periodically monitor potassium, creatinine, and uric acid levels. There is limited experience with the use of this drug in patients who have undergone renal transplantation.
3) Patients with essential hyperaldosteronemia generally do not respond to drugs that have antihypertensive effects by inhibiting the renin-angiotensin-aldosterone system, so administration of this drug is not recommended for these patients.
4) Patients receiving diuretics should periodically check their blood electrolyte levels. Thiazide drugs, such as hydrochlorothiazide, can cause fluid or electrolyte imbalances (hypercalcemia, hypokalemia, hyponatremia, hypomagnesemia, and hypochloremic alkalosis). Thiazide diuretics reduce urinary calcium excretion and may cause a transient, mild increase in serum calcium levels.
5) Because marked hypercalcemia may be a sign of undisclosed hyperparathyroidism, thiazide diuretics should be discontinued before performing a parathyroid function test.
6) Hydrochlorothiazide can cause hypokalemia by increasing urinary potassium excretion in a dose-dependent manner. These effects appear to be less likely when combined with candesartan cilexetil. The risk of hypokalemia may be increased in patients with cirrhosis, patients with excessive diuretic effects, patients with inadequate electrolyte intake, and patients taking corticosteroids or adrenocorticotropic hormone (ACTH).
7) Although there are no reports related to the administration of this drug, administration of ACE inhibitors or angiotensin II receptor antagonists may cause hyperkalemia, especially in those with heart failure or renal failure.
8) Thiazides may increase magnesium excretion and cause hypomagnesemia.
9) Administration of thiazide diuretics may impair glucose tolerance, so dosage adjustment may be necessary when administering antidiabetic drugs such as insulin. Latent diabetes may develop during thiazide therapy. However, it is reported that there is little or no effect at the 12.5 mg dose contained in this drug. Thiazide diuretics increase blood uric acid levels and may cause gout in sensitive patients.
10) In patients whose vascular tone and renal function depend primarily on the renin-angiotensin-aldosterone system (e.g., patients with renal disease such as severe congestive heart failure or renal artery stenosis), the administration of other drugs that affect this system has been associated with the development of hypotension, azotemia, oliguria, or, in rare cases, acute renal failure. Although a similar possibility cannot be ruled out with angiotensin II receptor antagonists, this effect has not been reported with this drug. Like other antihypertensive drugs, excessive blood pressure reduction in patients with ischemic heart disease or atherosclerotic cerebrovascular disease can cause myocardial infarction or stroke.
11) Hypersensitivity reaction to hydrochlorothiazide can occur in patients with or without a history of allergies or bronchial asthma, but is more likely to occur in patients with such a history.
12) Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.
13) In patients treated with angiotensin II receptor antagonists, hypotension may occur during anesthesia and surgery due to blockade of the renin-angiotensin system. Very rarely, hypotension may be severe enough to require the use of intravenous fluids and/or vasopressors.
14) When using hydrochlorothiazide, a positive reaction may occur in a doping test.
15) During hemodialysis, blood pressure may become sensitive to AT1-receptor antagonists due to decreased plasma volume and activation of the renin-angiotensin-aldosterone system. Therefore, when administering this drug to hemodialysis patients, blood pressure must be carefully monitored and the dose titrated.
16) Choroidal effusion, acute myopia, and secondary angle-closure glaucoma: Hydrochlorothiazide, a sulfonamide, can cause choroidal effusion, acute and transient myopia, and acute angle-closure glaucoma with visual field defects. Decreased vision or eye pain appears as an acute symptom and generally occurs within hours to weeks after starting the drug. If acute angle-closure glaucoma is not treated, permanent vision loss can occur. If symptoms appear, discontinue hydrochlorothiazide administration as quickly as possible. If intraocular pressure is not controlled, prompt medical or surgical treatment should be considered. Risk factors for angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.
17) Acute respiratory toxicity
Very rare cases of severe acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary edema typically develops within minutes to hours after administration. Symptoms at onset include dyspnea, fever, pulmonary deterioration and hypotension. If ARDS is suspected, discontinue this medicine and provide appropriate treatment.
Hydrochlorothiazide should not be administered to patients who have previously experienced ARDS after taking hydrochlorothiazide.

6. Interaction
1) Dual blockade of the renin-angiotensin-aldosterone system (RAAS) by co-administration of angiotensin receptor antagonists, ACE inhibitors, or aliskiren is associated with an increased risk of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy with these drugs. Patients receiving this drug concomitantly with other drugs that act on RAAS should do so under the supervision of a healthcare professional and closely monitor blood pressure, renal function, and electrolytes. Do not administer this drug and aliskiren-containing preparations together in patients with diabetes or moderate to severe renal impairment (glomerular filtration rate <60mL/min/1.73m2).
2) Substances that have been investigated in clinical pharmacokinetic studies, such as candesartan cilexetil, include hydrochlorothiazide, warfarin, digoxin, oral contraceptives (i.e., ethinyl estradiol/levonorgestrel), glibenclamide, and nifedipine. No clinically significant pharmacokinetic interactions were observed in these studies.
3) The bioavailability of candesartan is not affected by food.
4) Candesartan is mainly excreted in urine and bile without being metabolized, and only a small amount is eliminated through hepatic metabolism (CYP2C9). Interaction studies showed no effects on CYP2C9 and CYP3A4. Laboratory data indicate that in vivo interactions with drugs metabolized by cytochrome p450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 are unlikely to occur.
5) The antihypertensive effect of this drug may be increased by other antihypertensive drugs.
6) The potassium-depleting action of hydrochlorothiazide may be aggravated by other drugs associated with potassium excretion and hypokalemia (e.g. other potassium-eluting diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid derivatives). Additionally, the risk of hypokalemia associated with the use of hydrochlorothiazide should be carefully considered when coadministered with drugs known to prolong the QT interval.
7) Based on the experience of using other drugs that affect the renin-angiotensin-aldosterone system, the combined use of this drug with potassium-sparing diuretics, potassium supplements, salt substitutes, or drugs that increase blood potassium concentration (e.g. heparin sodium, trimethoprim/sulfamethoxazole combination) may increase blood potassium concentration.
8) Hypokalemia or hypomagnesemia caused by diuretics may increase the cardiotoxicity of digitalis glycosides or antiarrhythmic drugs. When this drug is used in combination with these drugs, it is recommended to periodically monitor blood potassium levels.
9) A reversible increase in blood lithium concentration and toxicity has been reported when ACE inhibitors or hydrochlorothiazide are used in combination with lithium. Although there have been no reports of concurrent use with this drug, the possibility of similar effects cannot be ruled out, so it is recommended to carefully monitor blood lithium levels during concurrent use.
10) When angiotensin II receptor antagonists are coadministered with NSAIDs (e.g. selective COX-2 inhibitors, acetylsalicylic acid, and non-selective NSAIDs), the antihypertensive effect may be reduced.
11) Co-administration of angiotensin II receptor antagonists and NSAIDs may increase the risk of worsening renal dysfunction, including potential acute renal failure and increased serum potassium, especially in patients with pre-existing renal dysfunction. Caution should be exercised when co-administering in particular to the elderly and patients with reduced effective blood volume (volume depletion). When co-administered with this drug, provide patients with sufficient fluids and monitor renal function periodically after starting co-administration.
12) The diuretic, sodium excreting, and antihypertensive effects of hydrochlorothiazide may be reduced by nonsteroidal anti-inflammatory drugs.
13) Absorption of hydrochlorothiazide is reduced by colestipol or cholestyramine.
14) The effects of non-depolarizing muscle relaxants (e.g. tubocurarine) may be increased by hydrochlorothiazide.
15) Thiazide diuretics reduce calcium excretion and may increase blood calcium concentration. If calcium supplements or vitamin D must be prescribed, blood calcium levels should be monitored and the dosage adjusted appropriately.
16) The blood sugar-raising effect of beta-blockers and diazoxide may be increased by thiazides.
17) Anticholinergics (e.g. atropine, biperiden) may increase the bioavailability of thiazide diuretics due to their action of reducing gastrointestinal motility and gastric emptying rate.
18) Thiazides may increase the risk of adverse reactions caused by amantadine.
19) Thiazide drugs can reduce renal excretion of cytotoxic drugs (e.g. cyclophosphamide, methotrexate) and may increase their myelosuppressive action.
20) The risk of hypokalemia may increase during concurrent use with steroids or adrenocorticotropic hormone (ACTH).
21) Orthostatic hypotension may be worsened by concomitant use of alcohol, barbiturates, anesthetics, or opium alkaloid drugs.
22) Thiazide diuretics may impair glucose tolerance, so dose adjustment of antidiabetic drugs such as insulin may be necessary.
23) Hydrochlorothiazide can reduce the response of pressure-increasing amines (e.g., adrenaline), but it is not effective enough to block the pressure-increasing effect.
24) Hydrochlorothiazide may increase the risk of acute renal failure, especially when used in combination with high doses of iodinated contrast media.
25) There is no clinically significant interaction between hydrochlorothiazide and food.
26) It has been reported that this drug reduces the reactivity of blood vessel walls to vasopressor amines such as norepinephrine and increases the paralyzing effect of tubocurarine and similar compounds. Therefore, if this drug is being administered to a patient before surgery, caution should be exercised, such as temporarily discontinuing the administration.
27) Because of the risk of lactic acidosis caused by metformin, do not administer metformin and this drug together if the blood creatinine level is more than 1.5 mg/dl for men and 1.2 mg/dl for women.
28) Cyclosporine: Concurrent use with cyclosporine may increase the risk of hyperuricemia and gout-type complications.

7. Administration to pregnant and lactating women
1) This drug should not be administered during pregnancy. Patients taking this medication should be aware of this and consult their doctor before considering the possibility of becoming pregnant so that they can make an appropriate choice. If pregnancy is confirmed, treatment with this drug should be discontinued immediately and, if appropriate, other treatment should be initiated. Drugs that act directly on the renin-angiotensin system may cause damage and death to the fetus and newborn when administered during pregnancy. Exposure to angiotensin II receptor antagonists is known to cause fetal toxicity (reduced renal function, oligohydramnios, cranial osteogenesis imperfecta) and neonatal toxicity (renal failure, hypotension, hyperkalemia) in humans. There is limited experience with the use of hydrochlorothiazide during pregnancy, especially in the first trimester. Animal testing is not enough. Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide, use during the second and third trimesters may impair fetal-placental perfusion and cause reactions such as jaundice, impaired electrolyte balance, and thrombocytopenia in the fetus and newborn.
2) It has not been revealed whether candesartan is transferred into breast milk, but secretion of candesartan in breast milk was confirmed in experiments on rats. Hydrochlorothiazide is secreted through breast milk. Because there is a possibility of causing adverse reactions in breastfed infants, breastfeeding should be discontinued when administration of this drug is essential.

8. Administration to children
Safety and effectiveness for adolescents and children under 18 years of age have not been established.

9. Administration to elderly people
In general, excessive lowering of blood pressure is not desirable for elderly people (there is a risk of myocardial infarction, stroke, or worsening of renal function damage). Therefore, be cautious when administering to elderly people.

10. Effect on clinical test values
It may lower serum protein-bound iodine (PBI) in patients without thyroid disorders.

11. Treatment in case of overdose
1) Symptoms: Based on pharmacological evidence, the main symptoms of candesartan overdose would be symptomatic hypotension and dizziness. In one case of overdose report (administration of up to 672 mg of candesartan cilexetil), the patient recovered without any particular reaction. The main symptom of hydrochlorothiazide overdose is acute fluid and electrolyte loss. Symptoms such as dizziness, hypotension, dry mouth, tachycardia, ventricular arrhythmias, sedation/impaired consciousness, and muscle spasms may also occur.
2) Treatment: There is no special information on treatment in case of overdose of this drug. However, in case of overdose, the following methods are recommended. : In case of overdose, inducing vomiting or gastric lavage should be considered. If symptomatic hypotension occurs, symptomatic treatment should be administered and vital signs (pulse, respiration, temperature, etc.) should be monitored. The patient should be placed in a supine position with the legs raised, and if this is insufficient, isotonic saline solution should be injected to increase blood volume. If necessary, check and correct blood electrolyte and acidity balance.
If the above measures are insufficient, sympathomimetics may be administered.
Candesartan cannot be removed by hemodialysis, and it is not known whether hydrochlorothiazide can be removed by hemodialysis.

12. Precautions for storage and handling
1) Keep out of reach of children.
2) Removing medicines from their original container and storing them in another container may cause accidents due to misuse of medicines or cause a decrease in the quality of medicines, so store them in their original containers.

13. Others
There has been no research on whether this drug affects the ability to drive or operate machinery, but considering the pharmacological properties of this drug, it is unlikely to have any effect. When driving or operating machinery, you should consider that dizziness or malaise may occasionally occur during treatment for high blood pressure.

5. How to save
Airtight container, stored below 30℃

6. Packaging unit
30 tablets/bottle

7. Period of use
36 months from date of manufacture

Product Updates

Total 5items

No.Product NameDetailsDate of ChangeDownload
5Cansata Plus Tab.Precautions for use2026.02.12PDF0029_201007708_Precautions for use_Kansata Plus Tablet.pdf
4Cansata Plus Tab.Dosage, usage precautions2023.03.09PDFKansata Plus Tablet_Change Plan + Change Comparison Table.pdf
3Cansata Plus Tab.Precautions for use2019.01.25PDF0505_201007708_Precautions for use (Kansata Plus tablet).pdf
2Cansata Plus Tab.Precautions for use2018.07.31PDF0084_201007708_Precautions for use (Kansata Plus tablet).pdf
1Cansata Plus Tab.Kansata Plus Tablet (Precautions for use)2014.01.09HWPKansata Plus change instructions.hwp